A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors
Trial Status: Active
This is a Phase 1 / 1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in subjects with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.
- Participant must have advanced Non-Small Cell Lung Cancer (NSCLC) that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit.
- Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
- Participant must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
- Participant has fresh and/or archived diagnostic formalin-fixed paraffin embedded (FFPE) tumor tissue confirmed available for analyses.
- Participant has adequate bone marrow, renal, and hepatic function.
- Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment.
- Participants in the combination therapy arms A and D must be eligible to receive erlotinib, or nivolumab per most current prescribing information, or at the discretion of the Investigator.
- Participants in the combination therapy Arm E must satisfy following criteria.
- Participant must have metastatic NSCLC with documented Epidermal Growth Factor Receptor (EGFR) mutation(s) known to be sensitive to osimertinib, including del19, L858R, G719X or L861Q.
- Participant must have discontinued osimertinib due to disease progression.
- Participant must have available post-progression tumor tissue for central c-Met immunohistochemistry (IHC) testing.
- Participant has received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within a period of 21 days or herbal therapy within 7 days prior to the first dose of ABBV-399.
- Participant has uncontrolled metastases to the central nervous system (CNS) based on head CT or MRI. Subjects with brain metastases may be eligible 2 weeks after definitive therapy to all known sites of CNS disease provided they are asymptomatic and either off or on a non-increasing dose (in last 2 weeks) of systemic steroids and not on anticonvulsants for seizure activity directly related to progressive CNS metastases.
- Participant has history of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis.
- Participant has unresolved clinically significant adverse events >= Grade 2 from prior anticancer therapy, except for alopecia or anemia.
- Participant has had major surgery within 21 days prior to the first dose of ABBV-399.
- Participant has a clinically significant condition(s) described in the protocol.
- Participant has history of major immunologic reaction to any Immunoglobulin G (IgG) containing agent.
- Participants enrolled on the combination therapy phase must satisfy the above exclusion criteria and also the following:
- Participants may not receive ABBV-399 in combination with osimertinib, erlotinib or nivolumab if they have any medical condition which in the opinion of the Investigator places the participant at an unacceptably high risk for toxicities from the combination.
City of Hope Comprehensive Cancer Center
UCLA / Jonsson Comprehensive Cancer Center
UC Irvine Health / Chao Family Comprehensive Cancer Center
University of California Davis Comprehensive Cancer Center
University of Colorado Hospital
Contact: Ross Camidge
University of Chicago Comprehensive Cancer Center
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Contact: Mark Awad
Massachusetts General Hospital Cancer Center
Siteman Cancer Center at Christian Hospital
Siteman Cancer Center at Washington University
Duke University Medical Center
M D Anderson Cancer Center
Trial Phase Phase I
Trial Type Treatment
- Primary ID M14-237
- Secondary IDs NCI-2014-00926, 2014-003154-14
- Clinicaltrials.gov ID NCT02099058